BIO-KOREA
20.4.2021 14:03:04 CEST | Business Wire | Press release
The 16th edition of BIO KOREA , the reference B2B event for global biotech and health industry professionals interested in opportunities in the Asian region, will be held online from 9th to 21st June 2021 with an onsite show at COEX in Seoul from 9th to 11th June.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005089/en/
In the global market, the bio-health industry is notching an annual average growth rate of 4 percent, higher than the shipbuilding and auto-making industry at 2.9 percent and at 1.5 percent, respectively. Especially, the Korean bio-health industry shows remarkable growth – its bio-health industry set a new milestone in outbound shipments with a 50 percent jump last year, led by robust demand for COVID-19 test kits and biosimilar products. With the record high export figures, the bio-health sector joins the ranks of the mainstay export industry for the first time in its history.
The game-changers of the industry in Korea such as the innovative pharmaceutical and medical device companies, start-ups in the digital health and biotech industries, and K-Quarantine-related companies would be available to meet at BIO KOREA 2021.
Based on the experience of last BIO KOREA 2020 which had been held only as a digital event, the BIO KOREA 2021 will run online and onsite as a hybrid format, running a digital platform available for all stakeholders unable to travel to Korea due to COVID-19.
BIO KOREA 2021 will connect companies and professionals to find new business opportunities and enhance the capacity for global networking.
Under the main theme of “New Normal: Breaking Barriers with Bio Innovation”, BIO KOREA 2021 consists of five main programs including Conference, Business Forum (Partnering and Company Presentation), Exhibitions, Invest Fair, and Job Fair.
BIO KOREA 2021 will create an arena where in-depth academic knowledge and innovative entrepreneurial ideas are exchanged by way of a Conference and Business Forum partnering through the hybrid conference. Through the Business Forum, BIO KOREA has given the chance to partner with 600+ companies from the globe every year. It will also provide invaluable opportunities for general investors and the public to directly participate in the global biotech industry at Invest Fair and Job Fair.
More information about BIO KOREA 2021 is available on the website: http://www.biokorea.org .
About BIO KOREA
BIO KOREA serves as a venue place for practical business correspondence as well as international information and technology exchange, invigorating the bio industry. For 16 years, BIO KOREA has been a place of bringing together various international academics, professionals, and CEOs of global bio companies to obtain, exchange, and discuss diverse affairs. It has been providing abundant opportunities to enhance competitive edges within the convergence industry centered around biotechnology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005089/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press release
QTSP status allows for full control over the digital trust value chain from identity verification to qualified electronic signature (QES) issuance Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity ve
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom